- About Us
- Media Release
- Our Clients
- Media Mentions
- Subscription Model
- Contact Us
The Global Prefilled Syringes Market size is expected to reach $11.9 billion by 2028, rising at a market growth of 10.5% CAGR during the forecast period.
A single-dose packet of vaccination attached with a needle on it is referred to as prefilled syringes. In addition, metal or glass syringes were once common, although there is a growing trend toward plastic & disposable syringes to keep the needle safe and prevent re-use (prefilled disposable systems). This has increased the demand for prefilled syringes over traditional glass vials for packing prescription medications in the healthcare industry.
When a syringe is placed into a medicine vial to pull out a dose; it offers another possible admixture-related risk of contamination. The prefilled syringes lessen the danger of drug contamination. By removing this risk, pre-sterilized syringes improve safety and do not require additional on-site vial cleanliness and depyrogenation steps. The market for prefilled syringes is expanding as a result of factors including the expansion of home healthcare services, rising use of injectable medications, an increase in the prevalence of chronic diseases, and a surge in the advantages of prefilled syringes over traditional vials. In addition, prefilled syringe-related technology developments aid in the market's expansion.
Additionally, the development of biologics and biosimilars as well as the rise in demand for injectable medications in prefilled forms present profitable potential for market expansion. Prefilled Syringes guarantee the administration of a solution that is free of particles and can hold volumes which commonly vary from 0.25 to 5.0 ml. They are thus most appropriate for products injected subcutaneously or intramuscularly.
The outbreak of the COVID-19 has impacted numerous domains of the business world. Because of the reduced danger of needle-stick injuries, prefilled syringes are more in demand than glass ampoules or any other extra needles. Hence, the producers have boosted the prefilled syringe manufacturing capacity in order to boost the COVID-19 vaccine output. Due to the surge in demand for home health care services, market participants have expanded their investments in resources and raw materials. Health care providers have adopted telemedicine, that assists to lessen face-to-face interaction, in response to innovative and numerous ways of providing the necessary quantity of care.
Prefilled syringes are frequently utilized in the therapy of chronic illnesses that allow patients to self-administer medication, such as diabetes, heart problems, and autoimmune diseases. Due to this, the market for prefilled syringes is expanding as a result of the increasing incidence and occurrence of chronic or life conditions around the world. Considering the comfort and safety of using self-injection equipment, there is also a rising demand for it. Better use-controlled drugs like narcotics, lower injection costs by requiring less preparation as well as fever material, simple storage and disposal, eradication of vials overfill for products moved to syringes for direct diluents are motivating patients to opt for prefilled syringes for treatment.
The growth of the prefilled syringes market is anticipated to be driven by the rising demand for biological medications and expanding advances in injectable delivery systems. Top players have taken an interest in biological medications since they focus on disorders for which there are no or few effective treatments. For example, F. in April 2021 U.S.-based Hoffmann-La Roche Ltd. The prefilled syringe of omalizumab known as Xolair has received FDA approval for its additional biologics application.
Prefilled syringes improve patient safety by reducing the risk of accidental needle sticking and dangerous product exposure that may occur while drawing medication from vials. Prefilled syringes' contaminated needles have been linked to blood-borne illnesses like HIV and HCV in similar people. Additionally, due to their difficult and expensive production process, the market presence of half prefilled syringes with interlaced safety elements is a serious problem.
On the basis of application, the prefilled syringes market is divided into Anaphylaxis, Rheumatoid Arthritis, Diabetes, and Others. Rheumatoid Arthritis segment recorded a substantial revenue share in the prefilled syringes market in 2021. The immune system of the body destroys its own tissue, especially joints, in rheumatoid arthritis. Internal organs are attacked in extreme cases. Joint linings are impacted by rheumatoid arthritis, which results in painful swelling. Along with that, there are many companies that are offering prefilled syringes for treating Rheumatoid Arthritis.
By therapeutics, the prefilled syringes market is classified into Large Molecules and Small Molecules. Small molecules segment procured a significant revenue share in the prefilled syringes market in 2021. The term "small molecule prefilled syringe" refers to the pharmacological formulation of such small molecule medications that are sold in prefilled syringes. Prefilled small molecule syringes have become an alternative to conventional dose forms including tablets and capsules. Glass, plastic, or polymer syringes that are empty are filled with a solution of the active pharmaceutical ingredient.
On the basis of material, the prefilled syringes market is bifurcated into Glass-based and Plastic-based. Glass-based segment procured the largest revenue share in the prefilled syringes market in 2021. It is because prefilled syringe technology has advanced, more people are using them, there are more chronic conditions, and utilizing prefilled syringes has more advantages than using normal vials. Glass syringes are simple to operate and, for medical experts, test for any particulate contaminants. Glass is a trustworthy choice because of its clarity and inertness, which guarantee the safety of the dose.
Based on design, the prefilled syringes market is segmented into Single-chamber Prefilled Syringes, Dual-chamber Prefilled Syringes and Customized Prefilled Syringes. Single-chamber Prefilled Syringes segment garnered the maximum revenue share in the prefilled syringes market in 2021. This is because demand for prefilled syringes is rising, there are more advantages from using them, and chronic diseases are becoming more common. Single-chamber prefilled syringes provide many benefits over vials, including improved API use with less overfill, less material needs, very little drug waste in clinical studies, and ease of and disposal.
|Market size value in 2021
|USD 5.9 Billion
|Market size forecast in 2028
|USD 11.9 Billion
|2018 to 2020
|2022 to 2028
|Revenue Growth Rate
|CAGR of 10.5% from 2022 to 2028
|Number of Pages
|Number of Tables
|Market Trends, Revenue Estimation and Forecast, Segmentation Analysis, Regional and Country Breakdown, Competitive Landscape, Companies Strategic Developments, Company Profiling
|Design, Material, Therapeutics, Application, Region
|US, Canada, Mexico, Germany, UK, France, Russia, Spain, Italy, China, Japan, India, South Korea, Singapore, Malaysia, Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria
Region-wise, the prefilled syringes market is analyzed across North America, Europe, Asia Pacific and LAMEA. Europe emerged as the leading region in the prefilled syringes market with the maximum revenue share in 2021. This is due to the rise in the prevalence of chronic diseases, an upsurge in the demand for prefilled syringes, the accessibility of cutting-edge healthcare facilities with skilled medical personnel, a boost in the number of R&D activities combined with a significant existence of important players, and a rise in government investment in the medical system.
Free Valuable Insights: Global Prefilled Syringes Market size to reach USD 11.9 Billion by 2028
The major strategies followed by the market participants are Product Launches. Based on the Analysis presented in the Cardinal matrix; Abbott Laboratories and Medtronic plc are the forerunners in the Prefilled Syringes Market. Companies such as Becton, Dickinson and Company, Gerresheimer AG and West Pharmaceutical Services, Inc. are some of the key innovators in Prefilled Syringes Market.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Bayer AG, Baxter International, Inc., Becton, Dickinson and Company, Gerresheimer AG, Medtronic PLC, Nipro Corporation, Terumo Corporation, Vetter Pharma, West Pharmaceutical Services, Inc.
The global Prefilled Syringes Market size is expected to reach $11.9 billion by 2028.
Increasing Number of Target Complaints and Improving Healthcare Infrastructure are driving the market in coming years, however, Lack of Prefilled Syringes with Intertwined Safety Characteristics restraints the growth of the market.
Abbott Laboratories, Bayer AG, Baxter International, Inc., Becton, Dickinson and Company, Gerresheimer AG, Medtronic PLC, Nipro Corporation, Terumo Corporation, Vetter Pharma, West Pharmaceutical Services, Inc.
The Large Molecules market acquired highest revenue in the Global Prefilled Syringes Market by Therapeutics in 2021; thereby, achieving a market value of $8.2 billion by 2028.
The Diabetes market is leading the Global Prefilled Syringes Market by Application in 2021; thereby, achieving a market value of $5.3 billion by 2028.
The Europe market dominated the Global Prefilled Syringes Market by Region in 2021; thereby, achieving a market value of $4.0 billion by 2028.
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.